Superficial Vein Thrombosis: Gregory Piazza Leads JAMA Review Addressing An Underrecognized Challenge
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, posted on LinkedIn:
”Superficial vein thrombosis is a challenging venous thromboembolic disorder because of the paucity of randomized controlled trial data and limited guidance in the literature. Despite this, the patient burden is high. Accordingly, clinicians are often left to “fend for themselves”. Very proud of this review in JAMA from my research team that gives clinicians and patients some pathways forward. Our research fellow and a first year medical student at Tufts, Darsiya Krishnathasan, started this as her undergraduate thesis. An incredible effort with amazing guidance from my colleague, Dr. Behnood Bikdeli. ”
Read the full review here.
Title: Superficial Vein Thrombosis: A Review
Authors: Gregory Piazza, Darsiya Krishnathasan, Nada Hamade, Francisco Ujueta, Giovanni Scimeca, Marcos D. Ortiz-Rios, Bridget McGonagle, Jean-Philippe Galanaud, David Jiménez, Manuel Monreal, John Fanikos, Anahita Dua, Leben Tefera, Raghu Kolluri, Sahil A. Parikh, Walter Ageno, Samuel Z. Goldhaber, Jeffrey I. Weitz, Lisa K. Moores, Isabelle Quéré, Behnood Bikdeli
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal